Completed PHASE1 INTERVENTIONAL 2-arm NCT01999725

Evaluation of the Safety and Pharmacokinetics of a Single Oral Dose of EDP-788

A Randomized, Double-Blind, Placebo-Controlled, Ascending One-Day (Single and Divided Dose) Safety, Tolerability, and Pharmacokinetic Study of EDP-788 in Healthy Adult Volunteers

Sponsor: Enanta Pharmaceuticals, Inc

Conditions Safety in Normal Volunteers

Interventions EDP-788 Placebo

Updated 7 times since 2017 Last updated: Jan 7, 2015 Started: Jan 31, 2014 Primary completion: Sep 30, 2014 Completion: Sep 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Safety in Normal Volunteers and is currently completed. Enanta Pharmaceuticals, Inc leads this study, which shows 7 recorded versions since 2014 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Nov 2022 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Nov 2022 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jan 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Enanta Pharmaceuticals, Inc

Data source: Enanta Pharmaceuticals, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Austin, United States